TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Feeding America's Bravest: Mediterranean Diet-Based Interventions to Change Firefighters' Eating Habits and Improve Cardiovascular Risk Profiles
Brief Summary: The purpose of this study is to modify the food culture of the fire service by motivating firefighters and their families to incorporate Mediterranean diet principles at work and home through behavior change strategies that involve education, participation and incentives. The ultimate purpose is to lower firefighters' risks for CVD and cancer by successfully getting more firefighters and their families to adopt and incorporate the healthy eating principles behind the Mediterranean diet.


Options:
A: Arm Label: Veg Group; Type: EXPERIMENTAL; Interventions: Other: Vegetarian diet, Other: Mediterranean diet | Arm Label: Med group; Type: ACTIVE_COMPARATOR; Interventions: Other: Vegetarian diet, Other: Mediterranean diet | Intervention Type: OTHER; Name: Vegetarian diet; Assigned to Arm(s): Med group, Veg Group | Intervention Type: OTHER; Name: Mediterranean diet; Assigned to Arm(s): Med group, Veg Group
B: Arm Label: Low Fat Diet; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Low Fat Diet | Arm Label: Mediterranean Diet; Type: EXPERIMENTAL; Interventions: Behavioral: Mediterranean Diet | Intervention Type: BEHAVIORAL; Name: Mediterranean Diet; Assigned to Arm(s): Mediterranean Diet | Intervention Type: BEHAVIORAL; Name: Low Fat Diet; Assigned to Arm(s): Low Fat Diet
C: Arm Label: Mediterranean Diet Intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: Mediterranean diet Intervention | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Mediterranean diet Intervention; Assigned to Arm(s): Mediterranean Diet Intervention group
D: Arm Label: New Nordic Diet; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary intervention | Arm Label: Average Danish Diet; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary intervention | Intervention Type: BEHAVIORAL; Name: Dietary intervention; Assigned to Arm(s): Average Danish Diet, New Nordic Diet

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Feeding America's Bravest: Mediterranean Diet-Based Interventions to Change Firefighters' Eating Habits and Improve Cardiovascular Risk Profiles
Brief Summary: The purpose of this study is to modify the food culture of the fire service by motivating firefighters and their families to incorporate Mediterranean diet principles at work and home through behavior change strategies that involve education, participation and incentives. The ultimate purpose is to lower firefighters' risks for CVD and cancer by successfully getting more firefighters and their families to adopt and incorporate the healthy eating principles behind the Mediterranean diet.


Options:
A: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Employee wellness programme | Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Comparator (Once off educational session and educational materials) | Intervention Type: BEHAVIORAL; Name: Employee wellness programme; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Comparator (Once off educational session and educational materials); Assigned to Arm(s): Control group
B: Arm Label: Intervention Group; Type: EXPERIMENTAL; Interventions: Other: Weight loss intervention | Arm Label: Control Group (delayed intervention); Type: EXPERIMENTAL; Interventions: Other: Weight loss intervention | Intervention Type: OTHER; Name: Weight loss intervention; Assigned to Arm(s): Control Group (delayed intervention), Intervention Group
C: Arm Label: Mediterranean Diet Intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: Mediterranean diet Intervention | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Mediterranean diet Intervention; Assigned to Arm(s): Mediterranean Diet Intervention group
D: Arm Label: Steps to Health; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Steps to Health | Arm Label: Steps to Health Plus!; Type: EXPERIMENTAL; Interventions: Behavioral: Steps to Health Plus! | Arm Label: Observational Comparison; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Steps to Health; Assigned to Arm(s): Steps to Health | Intervention Type: BEHAVIORAL; Name: Steps to Health Plus!; Assigned to Arm(s): Steps to Health Plus!

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Preimplantation Genetic Screening in Patients With Male Factor Infertility
Brief Summary: This will be a prospective, randomized (1:1 ratio) clinical trial for patients with severe male-factor infertility with or without preimplantation genetic screening (PGS). Qualified 450 patients are randomized into either of two groups: group A will undergo intracytoplasmic sperm injection (ICSI) without PGS (225 cases), Group B will undergo ICSI with PGS (225 cases). The partners of all participants will receive the same protocol for ovarian stimulation and standardized luteal phase support.

The target population will be patients with severe male-factor infertility aged between 20 and 55 years, diagnosed by the ESHER Criteria (Non-obstructive oligospermia，asthenspermia). Women with other reasons of infertility (eg. advanced age, anovulation, endometriosis, and premature ovarian failure) are excluded.

The randomization will take place 3-6 days after the oocyte pick-up day by a computer randomization system. The pregnancy test results, pregnancy complications, congenital anomalies, neonatal complications will be followed up by checking medical records and telephone calls.


Options:
A: Arm Label: Biopsy catheter; Type: EXPERIMENTAL; Interventions: Procedure: Endometrial biopsy | Intervention Type: PROCEDURE; Name: Endometrial biopsy; Assigned to Arm(s): Biopsy catheter | Intervention Type: PROCEDURE; Name: Endometrial Biopsy; Assigned to Arm(s): Biopsy catheter
B: Arm Label: PGS (genetic screening); Type: EXPERIMENTAL; Interventions: Diagnostic Test: Preimplantation Genetic Screening | Arm Label: no PGS (no genetic screening); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIAGNOSTIC_TEST; Name: Preimplantation Genetic Screening; Assigned to Arm(s): PGS (genetic screening)
C: Arm Label: local ingury; Type: ACTIVE_COMPARATOR; Interventions: Procedure: local injury | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: local injury; Assigned to Arm(s): local ingury
D: Arm Label: ICSI without PGS; Type: EXPERIMENTAL; Interventions: Procedure: ICSI without PGS | Arm Label: ICSI with PGS; Type: EXPERIMENTAL; Interventions: Procedure: ICSI with PGS | Intervention Type: PROCEDURE; Name: ICSI without PGS; Assigned to Arm(s): ICSI without PGS | Intervention Type: PROCEDURE; Name: ICSI with PGS; Assigned to Arm(s): ICSI with PGS

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Motivational Interviewing to Support Oral AntiCoagulation Adherence in Patients With Non-valvular Atrial Fibrillation (MISOAC-AF): A Prospective Randomized Clinical Study
Brief Summary: The purpose of the study is to investigate the impact of motivational interviewing in the adherence of patients with AF to oral anticoagulation (OAC) regimens. Patients assigned to the intervention group will be interviewed and guided on the importance of adherence to OAC medication, and will be contacted at 1 week, 2 months, 6 months and 1 year after discharge for educational interactive sessions. Patients in the control group will receive usual treatment and will be contacted at 1 year after discharge.


Options:
A: Arm Label: Specialized AF-clinic; Type: EXPERIMENTAL; Interventions: Other: Specialized outpatient AF Clinic | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Intervention Type: OTHER; Name: Specialized outpatient AF Clinic; Assigned to Arm(s): Specialized AF-clinic | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual Care
B: Arm Label: Immediate Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: risk reduction | Arm Label: Delayed Intervention; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: risk reduction | Intervention Type: BEHAVIORAL; Name: risk reduction; Assigned to Arm(s): Delayed Intervention, Immediate Intervention
C: Arm Label: Subject on Motivational Interview; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational interview | Arm Label: Subject Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Control | Intervention Type: BEHAVIORAL; Name: Motivational interview; Assigned to Arm(s): Subject on Motivational Interview | Intervention Type: BEHAVIORAL; Name: Control; Assigned to Arm(s): Subject Control
D: Arm Label: Novel integrated care concept (NICC); Type: EXPERIMENTAL; Interventions: Other: Novel integrated care concept (NICC) | Arm Label: Standard care; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard care | Intervention Type: OTHER; Name: Novel integrated care concept (NICC); Assigned to Arm(s): Novel integrated care concept (NICC) | Intervention Type: OTHER; Name: Standard care; Assigned to Arm(s): Standard care

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The investigators study will recruit IgA nephropathy patients with proteinuria range from 0.75 to 3.5g/d even after three-month treatment by sufficient ACEi/ARB. The patients were treated with Hydroxychloroquine 200-400mg/d according to eGFR. The proteinuria will recorded every two months and total four months. Then, the drug will be stopped for two months for observation of change of proteinuria.


Options:
A: Arm Label: sparsentan; Type: EXPERIMENTAL; Interventions: Drug: sparsentan | Arm Label: irbesartan; Type: ACTIVE_COMPARATOR; Interventions: Drug: irbesartan | Arm Label: dapagliflozin + sparsentan (Sub study); Type: EXPERIMENTAL; Interventions: Drug: sparsentan, Drug: Dapagliflozin | Arm Label: sparsentan (Sub Study); Type: EXPERIMENTAL; Interventions: Drug: sparsentan | Intervention Type: DRUG; Name: sparsentan; Assigned to Arm(s): dapagliflozin + sparsentan (Sub study), sparsentan, sparsentan (Sub Study) | Intervention Type: DRUG; Name: irbesartan; Assigned to Arm(s): irbesartan | Intervention Type: DRUG; Name: Dapagliflozin; Assigned to Arm(s): dapagliflozin + sparsentan (Sub study)
B: Arm Label: Hydroxychloroquine Sulfate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Hydroxychloroquine Sulfate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Hydroxychloroquine Sulfate; Assigned to Arm(s): Hydroxychloroquine Sulfate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Control Group; Type: EXPERIMENTAL; Interventions: Drug: Immunosuppressants, Other: Optimized Supportive Care, Other: Yi-Qi-Qing-Jie herbal compound placebo | Arm Label: YQF Group; Type: EXPERIMENTAL; Interventions: Drug: The Yi-Qi-Qing-Jie herbal compound, Drug: Immunosuppressants, Other: Optimized Supportive Care | Intervention Type: DRUG; Name: The Yi-Qi-Qing-Jie herbal compound; Assigned to Arm(s): YQF Group | Intervention Type: DRUG; Name: Immunosuppressants; Assigned to Arm(s): Control Group, YQF Group | Intervention Type: OTHER; Name: Optimized Supportive Care; Assigned to Arm(s): Control Group, YQF Group | Intervention Type: OTHER; Name: Yi-Qi-Qing-Jie herbal compound placebo; Assigned to Arm(s): Control Group
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: supportive therapy with: ACE-inhibitor / ARB / Statin | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: supportive and immunosuppressive therapy | Intervention Type: DRUG; Name: supportive therapy with: ACE-inhibitor / ARB / Statin; Assigned to Arm(s): A | Intervention Type: DRUG; Name: supportive and immunosuppressive therapy; Assigned to Arm(s): B

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: RENal Hemodialysis Patients ALlocated Apixaban Versus Warfarin in Atrial Fibrillation (RENAL-AF) Randomized Clinical Trial
Brief Summary: This is a prospective, randomized, open-label, blinded end-point evaluation trial. The patient population consists of patients on hemodialysis who have atrial fibrillation (AF) and end-stage renal disease (ESRD) .


Options:
A: Arm Label: heparin anticoagulation; Type: ACTIVE_COMPARATOR; Interventions: Drug: Heparin | Arm Label: citrate anticoagulation; Type: EXPERIMENTAL; Interventions: Drug: Citrate | Intervention Type: DRUG; Name: Heparin; Assigned to Arm(s): heparin anticoagulation | Intervention Type: DRUG; Name: Citrate; Assigned to Arm(s): citrate anticoagulation
B: Arm Label: Vitamin K antagonist; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: rivaroxaban; Type: ACTIVE_COMPARATOR; Interventions: Drug: rivaroxaban | Arm Label: rivaroxaban and vitamin K2; Type: ACTIVE_COMPARATOR; Interventions: Drug: rivaroxaban, Dietary Supplement: Vitamin K2 | Intervention Type: DRUG; Name: rivaroxaban; Assigned to Arm(s): rivaroxaban, rivaroxaban and vitamin K2 | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin K2; Assigned to Arm(s): rivaroxaban and vitamin K2
C: Arm Label: Apixaban; Type: ACTIVE_COMPARATOR; Interventions: Drug: Apixaban | Arm Label: Vitamin-K antagonists (Phenprocoumon); Type: ACTIVE_COMPARATOR; Interventions: Drug: Phenprocoumon | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): Apixaban | Intervention Type: DRUG; Name: Phenprocoumon; Assigned to Arm(s): Vitamin-K antagonists (Phenprocoumon)
D: Arm Label: apixaban; Type: EXPERIMENTAL; Interventions: Drug: apixaban | Arm Label: warfarin; Type: EXPERIMENTAL; Interventions: Drug: warfarin | Intervention Type: DRUG; Name: apixaban; Assigned to Arm(s): apixaban | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): warfarin

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Clinical Impact of Telemedicine in Crohn's Disease and Ulcerative Colitis: Study Teccu
Brief Summary: Pragmatic clinical trial, randomized, controlled parallel, 3 group (group technology platform, call group and control group), developed in the monograph Reference Unit of Inflammatory Bowel Disease Valencia (single-center).


Options:
A: Arm Label: HealthPROMISE users; Type: EXPERIMENTAL; Interventions: Other: HealthPROMISE users | Arm Label: Control Group; Type: PLACEBO_COMPARATOR; Interventions: Other: Control Group | Intervention Type: OTHER; Name: HealthPROMISE users; Assigned to Arm(s): HealthPROMISE users | Intervention Type: OTHER; Name: Control Group; Assigned to Arm(s): Control Group
B: Arm Label: Telemedicine group; Type: EXPERIMENTAL; Interventions: Device: Telemedicine | Arm Label: Telephone support group; Type: EXPERIMENTAL; Interventions: Device: Telephone | Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Other: Conventional care | Intervention Type: DEVICE; Name: Telemedicine; Assigned to Arm(s): Telemedicine group | Intervention Type: DEVICE; Name: Telephone; Assigned to Arm(s): Telephone support group | Intervention Type: OTHER; Name: Conventional care; Assigned to Arm(s): Control group
C: Arm Label: Standard care; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard care | Arm Label: myIBDcoach; Type: EXPERIMENTAL; Interventions: Other: myIBDcoach | Intervention Type: OTHER; Name: myIBDcoach; Assigned to Arm(s): myIBDcoach | Intervention Type: OTHER; Name: Standard care; Assigned to Arm(s): Standard care
D: Arm Label: Wait List; Type: OTHER; Interventions: Behavioral: Wait list comparison group | Arm Label: 2 phone sessions; Type: EXPERIMENTAL; Interventions: Behavioral: 2 Family-based problem solving phone sessions | Arm Label: 4 phone sessions; Type: EXPERIMENTAL; Interventions: Behavioral: 4 Family-based problem solving phone intervention sessions | Intervention Type: BEHAVIORAL; Name: 2 Family-based problem solving phone sessions; Assigned to Arm(s): 2 phone sessions | Intervention Type: BEHAVIORAL; Name: 4 Family-based problem solving phone intervention sessions; Assigned to Arm(s): 4 phone sessions | Intervention Type: BEHAVIORAL; Name: Wait list comparison group; Assigned to Arm(s): Wait List

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison of Regional Ventilation Pattern During High Flow Nasal Cannula Between Conventional Low Flow System Nasal Cannula in Patients With Mild to Moderate Hypoxia
Brief Summary: High-flow nasal cannula (HFNC) that uses heated and humidified oxygen was recently introduced for bedside care. It has been shown to be associated with reduced risks of tracheal intubation rates and mortality in adult hypoxic patients.

The mechanisms of the effects of HFNC are thought to be related to the favorable effects of the heated and humidified gas, the high-flow rate used to minimize the entrainment of room air, and an increase in the ventilation efficiency, including the elimination of nasopharyngeal dead space, positive end-expiratory pressure (PEEP) effects, and improvements in paradoxical abdominal movement. Regarding the effects on lung volume, global ventilation in the lungs increases during HFNC, which is thought to attribute to PEEP effects. However, how regional ventilation is affected during HFNC in comparison with conventional NC remains unknown.

Because PEEP in mechanically ventilated patients improves the regional homogeneity of ventilation, investigators postulated that HFNC via PEEP effects would result in more homogeneous regional distributions in the ventilation changes. Investigators therefore assessed global and regional ventilation in patients with hypoxia receiving care via HFNC using electric impedance tomography and compared these results with conventional nasal cannula.


Options:
A: Arm Label: Venturi mask; Type: ACTIVE_COMPARATOR; Interventions: Device: Venturi mask | Arm Label: Nasal high-flow; Type: ACTIVE_COMPARATOR; Interventions: Device: Nasal high-flow | Intervention Type: DEVICE; Name: Venturi mask; Assigned to Arm(s): Venturi mask | Intervention Type: DEVICE; Name: Nasal high-flow; Assigned to Arm(s): Nasal high-flow
B: Arm Label: HFNT; Type: EXPERIMENTAL; Interventions: Other: HFNT | Arm Label: NIV; Type: ACTIVE_COMPARATOR; Interventions: Other: NIV | Intervention Type: OTHER; Name: HFNT; Assigned to Arm(s): HFNT | Intervention Type: OTHER; Name: NIV; Assigned to Arm(s): NIV
C: Arm Label: CF patients HFN; Type: EXPERIMENTAL; Interventions: Device: High flow nasal oxygen cannula | Arm Label: CF patients NIV; Type: EXPERIMENTAL; Interventions: Device: Noninvasive ventilation | Intervention Type: DEVICE; Name: High flow nasal oxygen cannula; Assigned to Arm(s): CF patients HFN | Intervention Type: DEVICE; Name: Noninvasive ventilation; Assigned to Arm(s): CF patients NIV
D: Arm Label: HFNC first; Type: ACTIVE_COMPARATOR; Interventions: Device: HFNC followed by conventional nasal cannula | Arm Label: LFS first; Type: ACTIVE_COMPARATOR; Interventions: Device: Conventional nasal cannula followed by HFNC | Intervention Type: DEVICE; Name: HFNC followed by conventional nasal cannula; Assigned to Arm(s): HFNC first | Intervention Type: DEVICE; Name: Conventional nasal cannula followed by HFNC; Assigned to Arm(s): LFS first

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Gabapentin as an Adjunct to Paracervical Block for Perioperative Pain Management for Surgical Abortion: a Randomized Controlled Trial
Brief Summary: This is a randomized controlled trial of gabapentin 600 mg compared to placebo given 1-2 hours preoperatively in conjunction with perioperative paracervical block for surgical abortion. The researchers hypothesize that adding gabapentin to local anesthesia will reduce perioperative and postoperative pain associated with surgical abortion. Additionally, the researchers hypothesize that gabapentin will reduce nausea, vomiting, anxiety, and consumption of pain medication.


Options:
A: Arm Label: Gabapentin group; Type: EXPERIMENTAL; Interventions: Drug: Gabapentin | Arm Label: Placebo group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Gabapentin; Assigned to Arm(s): Gabapentin group | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo group
B: Arm Label: Nitrous oxide administration; Type: EXPERIMENTAL; Interventions: Other: Nitrous oxide administration | Arm Label: Standard care group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Nitrous oxide administration; Assigned to Arm(s): Nitrous oxide administration
C: Arm Label: Placebo group; Type: PLACEBO_COMPARATOR; Interventions: N/A | Arm Label: Paracervical block plus lidocaine spray; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paracervical block + lidocaine spray | Arm Label: paracervical block plus isotonic saline spray; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paracervical block | Arm Label: only lidocaine spray; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lidocaine spray | Intervention Type: DRUG; Name: Paracervical block; Assigned to Arm(s): paracervical block plus isotonic saline spray | Intervention Type: DRUG; Name: Lidocaine spray; Assigned to Arm(s): only lidocaine spray | Intervention Type: DRUG; Name: Paracervical block + lidocaine spray; Assigned to Arm(s): Paracervical block plus lidocaine spray
D: Arm Label: paracetamol; Type: ACTIVE_COMPARATOR; Interventions: Drug: paracetamol | Arm Label: without drug; Type: ACTIVE_COMPARATOR; Interventions: Other: without drug | Arm Label: dexketoprofen trometamol; Type: ACTIVE_COMPARATOR; Interventions: Drug: dexketoprofen trometamol | Arm Label: two puff xylocain administration on cervical surface; Type: ACTIVE_COMPARATOR; Interventions: Drug: suction curettage | Arm Label: paracervical block with ultracaine; Type: ACTIVE_COMPARATOR; Interventions: Drug: suction curettage | Intervention Type: DRUG; Name: paracetamol; Assigned to Arm(s): paracetamol | Intervention Type: DRUG; Name: dexketoprofen trometamol; Assigned to Arm(s): dexketoprofen trometamol | Intervention Type: DRUG; Name: suction curettage; Assigned to Arm(s): two puff xylocain administration on cervical surface | Intervention Type: DRUG; Name: suction curettage; Assigned to Arm(s): paracervical block with ultracaine | Intervention Type: OTHER; Name: without drug; Assigned to Arm(s): without drug

Answer: A